ICON Acquires PriceSpective
28 Fevereiro 2012 - 8:30AM
Business Wire
ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global
provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries, today announced the
acquisition of PriceSpective LLC, a global leader in value strategy
consulting. The acquisition strengthens ICON’s expertise in value
based pricing and market access, and together with the health
economics and patient reported outcomes services acquired through
Oxford Outcomes, enables ICON to offer the industry’s most
integrated regulatory, clinical and market access solution.
Headquartered in Philadelphia, and with offices in London, Los
Angeles, San Diego, Raleigh and Boston, PriceSpective is a premier
consultancy that has a strong reputation for excellence in
strategic pricing, market access, HEOR, due diligence support and
payer engagement services. Since the company’s inception in 2003,
PriceSpective has developed strategies for dozens of new product
launches, and hundreds of development and in-market products,
across 40+ disease areas.
Commenting on the acquisition, Ciaran Murray, CEO at ICON plc,
said: “Payers are increasingly demanding evidence not only of
product efficacy, but also value for money which has led to an
upsurge in client demand for research that links efficacy, value
and price. PriceSpective’s strategic expertise, coupled with its
strong network of relationships with thousands of payers and market
experts worldwide, makes it the perfect addition to our service
portfolio.”
Murray added, “The acquisition of PriceSpective, and Oxford
Outcomes in 2011, demonstrates our commitment to providing clients
with integrated service offerings to support early-stage,
pre-launch and post-launch decision making.”
“With a shared vision of an integrated approach to value,
pricing and access strategy, PriceSpective is delighted to join
forces with ICON to offer an expanded, leading edge service to our
clients,” said Steve Slovick, PriceSpective President. “The need
for manufacturers to embrace a paradigm of value-driven development
has never been greater, and the combined group has unparalleled
expertise, resources and insight to fully support our clients in
this area.”
About PriceSpective
PriceSpective is a value strategy consultancy that defines,
drives, and captures value for pharmaceutical and biotechnology
clients in today’s complex healthcare environment. The company
delivers expert guidance in integrated global pricing,
reimbursement and market access strategy with its depth of
experience and actively engaged senior leadership. PriceSpective is
headquartered in Philadelphia with offices in London, Los Angeles,
San Diego, Raleigh and Boston.
Further information is available at www.pricespective.com
About ICON plc
ICON plc is a global provider of outsourced development services
to the pharmaceutical, biotechnology and medical device industries.
The Company specialises in the strategic development, management
and analysis of programs that support clinical development - from
compound selection to Phase I-IV clinical studies. ICON currently
has around 8,500 employees, operating from 81 locations in 40
countries.
Further information is available at www.iconplc.com
DISCLOSURE NOTICE: This release contains, and our
officers and representatives may from time to time make,
"forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such
as: "anticipate," "intend," "plan," "expect," "strategy" and
similar references to future periods. Forward-looking statements
are neither historical facts nor assurances of future performance.
Instead, they are based only on our current beliefs, expectations
and assumptions regarding the future of our business, future plans
and strategies, anticipated events and trends, the economy and
other future conditions. Because forward-looking statements relate
to the future, they are subject to inherent uncertainties, risks
and changes in circumstances that are difficult to predict and many
of which are outside of our control. Our actual results may differ
materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking
statements. Important factors that could cause our actual results
to differ materially from those indicated in the forward-looking
statements include, among others, strategic actions, including our
success in integrating PriceSpective; general economic and
financial conditions; the extent to which we are successful in
implementing our strategy, gaining new, long-term relationships
with customers and retaining existing ones; the risk of competition
on our industry; developments and changes in laws and regulations;
and such other factors as discussed in Part I, Item 3 “Risk
Factors” in our Form 20-F for the fiscal year ended December 31,
2010. Any forward-looking statement made by us in this release is
based only on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
ICON/ICLR-F
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024